A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase the expression of inhibitory immune checkpoint molecules. We conducted the first randomized phase 2 study of azacitidine plus the immune checkpoint inhibitor durvalumab vs azacitidine monotherapy as first-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeidan, Amer M., Boss, Isaac, Beach, C. L., Copeland, Wilbert B., Thompson, Ethan, Fox, Brian A., Hasle, Vanessa E., Ogasawara, Ken, Cavenagh, James, Silverman, Lewis R., Voso, Maria Teresa, Hellmann, Andrzej, Tormo, Mar, O’Connor, Tim, Previtali, Alessandro, Rose, Shelonitda, Garcia-Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006291/
https://www.ncbi.nlm.nih.gov/pubmed/34972214
http://dx.doi.org/10.1182/bloodadvances.2021005487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006291/
https://www.ncbi.nlm.nih.gov/pubmed/34972214
http://dx.doi.org/10.1182/bloodadvances.2021005487

Ejemplares similares